Proceeds to be employed in the development of Icos Biologics
Copenhagen, Denmark -– CMC Biologics A/S (CMC, formerly CMC Biopharmaceuticals A/S) announced today that it has closed a share capital offering which was arranged as part of the Company's financial strategy in connection with its recent acquisition of ICOS Biologics Manufacturing. Funds managed by Monitor Clipper Partners, LLC (MCP or Monitor Clipper) led the transaction, which also included follow-on investments from EEP and other existing investors. The financing round also provided liquidity for certain original shareholders of CMC.
The financing will be employed for the development and build-out of ICOS Biologics Manufacturing facilities as well as for operational and working capital purposes.
CMC, a Copenhagen-Denmark based leading provider of contract biomanufacturing services, announced on December 4, 2007 the acquisition of Seattle, US based ICOS Biologics from Eli Lilly and Company (NYSE: LLY) and the subsequent formation of CMC ICOS Biologics Inc. This transaction expands CMC's operations into the United States, where CMC ICOS will continue to develop and manufacture therapeutic proteins for early clinical trials for its customers. The new share capital will allow significant development at the facility to enable production for late stage clinical trials and commercial biopharmaceuticals.
"We were attracted to CMC because of its highly impressive facilities, strong management team and excellent reputation among clients in the rapidly growing biologics manufacturing sector. The management team has worked together successfully for many years and has built up a great level of technical expertise" said Peter S Laino, General Partner at Monitor Clipper. "CMC has managed to create a diverse, high-quality client base and has demonstrated strong revenue growth. Now, with the recent acquisition of ICOS Biologics and its expansion into the US market, we see additional opportunity to accelerate this growth and achieve its long-term commercial and financial objectives."
"We are delighted to welcome Monitor Clipper as new investors in CMC. With an enlarged and sophisticated shareholder base and a strong balance sheet, CMC is now well-positioned to integrate its newly acquired US operations and offer a transatlantic high value adding service to our clients" said David Kauffmann, CMC's Chairman and General Partner of EEP. "We all share the vision of continuing to build a global leader in biologics manufacturing" added Thomas Balland, a CMC Director and Investment Director at Innoven Partenaires.
Mads Laustsen, CMC's CEO said, "We continue to experience strong demand for our services and 2008 is set to be another record breaking year. And with our recent acquisition of ICOS Biologics, we now have the ability to deliver a truly global service offering – taking our customers "from DNA to Commercial Product." Having a strong
international shareholder base not only provides us with the financial firepower and flexibility to execute these plans, but also increases our exposure in strategic markets such as North America, the UK and continental Europe."
Thomas Tscherning, Partner at BankInvest Biomedical Venture, said: "BankInvest has been a constant investor and board member since the inception of CMC in 2001. We are proud to include Monitor Clipper amongst the Company's shareholders, which we are confident will support the continued growth of the enlarged CMC operations."
William Blair & Company acted as the sole advisor in this transaction, having developed a long standing relationship with the Company and its shareholders from its previous financing round led by Innoven Partenaires in 2004.
About CMC Biologics
Based in Copenhagen, Denmark, CMC is a European leading contract development and manufacturing organization with sales offices located in Europe and the US. CMC provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, taking their projects from gene to licensed product. The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. Services include a comprehensive range of process and analytical development activities. The Company's modern, purpose built facility has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes. For further information, visit: www.cmcbio.com
About Monitor Clipper Partners
Monitor Clipper is a private equity investment firm formed in 1998 by The Monitor Group, a leading group of advisory businesses that has at its core one of the world's largest strategy consulting firms, and The Clipper Group, an experienced private equity investment firm. Monitor Clipper seeks to make private equity investments in middle-market companies in North America and Europe to which they can add significant value through the combined skills of their principals and privileged access to the proprietary resources of The Monitor Group. Monitor Clipper currently manages over $2.0 billion of capital and has invested over $1.3 billion since making its first investment in February 1999. For further information, visit: www.monitorclipper.com
About European Equity Partners
European Equity Partners (EEP) provides capital to fast growth companies in Northern Europe. Focusing on growth companies within Information Technology and Life Sciences, EEP not only provides capital, but also actively assists our portfolio companies in creating value. EEP focuses on investing in relatively few companies, resulting in each company getting more input and support from a tailored and dedicated EEP team. For further information, visit: www.eeplp.com
BankInvest is a leading independent Nordic asset manager of mutual funds, venture capital and discretionary mandates for institutional clients. Based on an active investment process, focused on trends that shape the future, we add value to our investors through extensive research, company visits, the use of industrial specialists and hands-on support in portfolio companies in the EU and the US. For further information, visit www.BIVenture.com and www.BankInvest.com
About Innoven Partenaires
Innoven Partenaires is an independent asset management company authorised by the Autorité des Marchés Financiers to manage venture capital funds. Founded in 1997, Innoven Partenaires currently manages 210 M€ via 15 FCPI funds, 7 of which are managed on behalf of La Poste. Innoven Partenaires invests in France and across Europe in young companies with high growth potential in the life sciences, information technology, communications and energy / cleantech sectors. The investment team has a pro-active approach, working closely with portfolio companies, making available a broad international network, in-depth mergers and acquisitions and business development experience and a strong track record in bringing companies to IPO. For further information, visit: www.innoven-partners.com
About William Blair
William Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, the firm has been committed to helping clients achieve their financial objectives. As an independent, employee-owned firm, its philosophy is to serve its clients' interests first and foremost. It places a high value on the enduring nature of its client relationships, the quality of its products and services, and the continuity and integrity of its people. William Blair & Company's offices include Chicago, Boston, London, New York, San Francisco, Shanghai, Tokyo, and Zurich.
The firm's international operation, headquartered in London for more than 20 years, manages cross-border transaction advisory services across its global offices with direct coverage of Europe, the Middle-East and Asia, and across industry sectors.
For further information, visit: www.williamblair.com
David Kauffmann, Chairman (CMC): + 44 7768 004 421
Mads Laustsen, CEO (CMC): +45 2948 8401